Skip to content

Aspirin and Cancer

Facebook
Twitter
LinkedIn

Aspirin is often considered a wonder drug due to its versatile use in treating inflammation, reducing pain, and helping to prevent heart-related disease. However, there is more to it. Aspirin is actually cancer-preventive. Studies have shown that a daily low dose of aspirin, medically prescribed for more than five years, lowers the risk of cancer-related deaths by at least 30%. So, should we all start taking aspirin on a daily basis to lower our chances of getting cancer?

No, not exactly. This is because many aspects of aspirin’s cancer-preventive effects are still poorly understood. Particularly, researchers have not yet pinpointed what enables aspirin to selectively kill early-stage cancer cells and not healthy cells. This is the scope of the research currently being carried out at the Yeast Molecular Biology and Biotechnology Laboratory (headed by Prof. Rena Balzan).

Maria Azzopardi

The secret behind aspirin’s tendency to kill certain cells but not others seems to lie in the physiology of the exposed cells. Aspirin exploits the natural differences between healthy and cancerous cells to eliminate malignant cells before they can take over.

Oxygen, if transformed into ‘Reactive Oxygen Species’, is known to cause DNA mutations that can lead to cancer. Through this research, we studied mutated yeast cells which are a relevant model of early-stage cancer cells due to their low tolerance to oxygen-associated stress. We then identified genes in these mutant yeasts which are affected by aspirin.

One of aspirin’s targets is a key metabolite required for the production of energy-rich compounds vital for cell survival. We found that aspirin creates a shortage of this metabolite in mutated yeast cells, causing them to run out of energy and die.

This implies that early-stage human cancer cells may suffer a similar fate and, more importantly, partly explains how aspirin prevents tumour formation. Such knowledge may prove useful in the development of novel anti-cancer treatments.


This research was carried out as part of Project “R&I-2015-001”, financed by the Malta Council for Science & Technology through the R&I Technology Development Programme. This research is being carried out as part of Azzopardi’s Ph.D. project at the Centre for Molecular Medicine & Biobanking and the Department of Physiology & Biochemistry, University of Malta
  Author: Maria Azzopardi

Author

More to Explore

Finding a Home in Malta

Getting on the property ladder is incredibly difficult. Unless you are fortunate enough that your parents already own several properties, you will most likely be stuck for the rest of your adult life paying off your first (and possibly only) one-bedroom apartment. Is this grim future set in stone, or are there more creative solutions?

A Decade of Open Access at UM

This year marks a significant milestone for UM as we celebrate the 10th anniversary of OAR@UM, the University’s Open Access Repository. Its role reflects UM’s commitment to enhance the visibility and dissemination of research output generated at UM.

3D Printing Balloons Inflates Enthusiasm for Future Technology

With the rise in popularity of 3D printing, the medium has become more accessible. What’s more, recent advancements in the field have made the technology rather intriguing. THINK explores the latest UM research on the development of 3D-printed balloons.

Comments are closed for this article!